InvestorsHub Logo
Followers 52
Posts 2230
Boards Moderated 0
Alias Born 07/06/2011

Re: arvitar post# 131482

Tuesday, 04/25/2017 10:27:35 PM

Tuesday, April 25, 2017 10:27:35 PM

Post# of 146196
All models are based on some assumptions.

One big assumption you make is that they won't be able to raise any more capital or get funding from a partner.

In fact, all developmental stage biotechs need to raise money to fund development costs until they have revenue coming in (greater than costs). Most biotches have even less cash on hand then NNVC - 11 months is what I recall reading recently (according to Reuters).

"It could also throw a lifeline to smaller biotech firms, which on average have only 11 months of cash left to finance their research, according to Thomson Reuters data, and have been hesitant to try to raise money during a weak equities market. "

http://www.reuters.com/article/us-usa-election-biotech-m-a-idUSKBN1360DChttp://www.reuters.com/article/us-usa-election-biotech-m-a-idUSKBN1360DC






Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News